News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Government
As Midterms Loom, White House Cracks Down on RFK Jr.’s Vaccine Policies—but MAHA Resists
March 16, 2026
·
4 min read
·
Tristan Manalac
Earnings
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
March 13, 2026
·
5 min read
·
Annalee Armstrong
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
·
1 min read
·
Jennifer C. Smith-Parker
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
March 11, 2026
·
2 min read
·
Tristan Manalac
